Literatur
-
1
American Thoracic Society .
Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).
Am J Respir Crit Care Med.
2000;
161
646-664
-
2
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias .
This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.
Am J Respir Crit Care Med.
2002;
165
277-304
-
3
Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C.
Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression.
Am J Respir Crit Care Med.
1997;
156
1897-901
-
4
Bjoraker J A, Ryu J H, Edwin M K. et al .
Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med.
1998;
157
199-203
-
5
Homolka J, Ziegenhagen M W, Gaede K I. et al .
Systemic immune cell activation in a subgroup of patients with idiopathic pulmonary fibrosis.
Respiration.
2003;
70
262-269
-
6
Katzenstein A L, Myers J L.
Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification.
Am J Respir Crit Care Med.
1998;
157
1301-1315
-
7
King T E, Schwarz M I, Brown K. et al .
Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality.
Am J Respir Crit Care Med.
2001;
164
1025-1032
-
8 Müller-Quernheim J. (Hrsg.) Interstitielle Lungenerkrankungen. Standards in Klinik, Diagnostik und Therapie. Thieme Verlag 2003
-
9
Niedermeyer J, Bewig B, Bickhardt T. et al .
Lungen- und Herz-Lungentransplantation. Leitlinien zur Indikationsstellung und präoperativen Diagnostik.
Pneumologie.
2001;
55
396-400
-
10
Raghu G, Johnson W C, Lockhart D, Mageto Y.
Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study.
Am J Respir Crit Care Med.
1999;
159
1061-1069
-
11
Selman M, King T E, Pardo A.
Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.
Ann Intern Med.
2001;
134
136-151
-
12
Thabut G, Mal H, Castier Y. et al .
Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis.
J Thorac Cardiovasc Surg.
2003;
126
469-475
-
13
Ziegenhagen M W, Rothe M E, Zissel G, Müller-Quernheim J.
Exaggerated TNF-alpha release of alveolar macrophages in corticosteroid resistant sarcoidosis.
Sarcoidosis Vasc Diffuse Lung Dis.
2002;
19
185-190
-
14
Ziegenhagen M W, Schrum S, Zissel G. et al .
Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis.
J Investig Med.
1998;
46
223-231
-
15
Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L H.
A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis.
N Engl J Med.
1999;
341
1264-1269
Dr. med. Manfred W. Ziegenhagen
Medizinische Klinik, Abteilung Pneumologie, Universitätsklinikum Freiburg
Killianstraße 5
79106 Freiburg
Telefon: 0761/2703731
Fax: 0761/2707437
eMail: ziegenhagen@med1.ukl.uni-freiburg.de
